Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Men Undergoing Androgen Deprivation Therapy
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
OUTLINE:
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
Washington
-
Seattle, Washington, 미국, 98109
- Fred Hutch/University of Washington
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Signed informed consent
- Histologically confirmed adenocarcinoma of the prostate
- Non-castrate disease with a serum testosterone level >= 50 ng/dL (1.73 nmol/L) at baseline
- No evidence of distant metastatic disease on baseline computed tomography-chest, abdomen and pelvis (CT-CAP) and bone scans
Patients will be stratified by the presence or absence of pre-existing cardiovascular disease defined as at least one of the following:
- Prior myocardial infarction >= 30 days before enrollment
Prior revascularization procedure >= 30 days before consent, including:
- Coronary artery stent placement or balloon angioplasty
- Coronary artery bypass graft surgery
- Stent placement or balloon angioplasty to a carotid, iliac, femoral, or popliteal artery
- Carotid endarterectomy surgery
- Vascular bypass surgery of the iliac, femoral, or popliteal artery
- Results from angiogram or CT angiogram of coronary, carotic, iliac, femoral, or popliteal arteries that documents at least one vascular stenosis >= 50% at any time point before enrollment
- Carotid ultrasound results that shows stenosis >= 50% at any time point before enrollment
- Ankle-brachial pressure index < 0.9 at any time point before enrollment
- Intent to initiate continuous androgen deprivation therapy (ADT) for at least 12 months
Exclusion Criteria:
- No prior treatment with ADT at time of study entry. (Prior neoadjuvant/adjuvant ADT is allowed only if the last injection of a depot formulation wore off at least 12 months prior to enrollment)
- Previous or concurrent hormonal or systemic therapy for prostate cancer including: anti-androgens, estrogens, megestrol acetate, ketoconazole, abiraterone, enzalutamide, or chemotherapy. (Prior or planned neoadjuvant bicalutamide for prevention of tumor flare is allowed)
- Plans to start or continue treatment with an investigational product after enrollment
- Poorly controlled type 1 or type 2 diabetes mellitus, based on hemoglobin A1c, as judged by the investigator
- Prior or planned surgical castration
- Poorly controlled hypertension at time of study entry, as judged by the investigator
- Myocardial infarction or stroke < 30 days prior to enrollment
- Coronary, carotid, or peripheral artery revascularization < 30 days prior to enrollment
- Planned or scheduled cardiac surgery or percutaneous coronary intervention (PCI) procedure that is known at the time of enrollment
- Mental incapacity or language barrier precluding adequate understanding or cooperation
- Inability to tolerate magnetic resonance imaging (MRI) imaging, or both Lupron and Degarelix
- Any other clinically significant disorder which may affect the subject's health or the outcome of the trial as judged by the investigator
- Estimated glomerular filtration rate (eGFR) < 45
- History of allergy to gadolinium contrast agent
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Clinical Evaluations
Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
|
보조 연구
Undergo clinical evaluations
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in visual characterization of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results after Andorgen Deprivation Therapy
기간: 12 Months
|
Change From Baseline visual characterization scan results at 12 months
|
12 Months
|
|
Change standardized uptake values of 18F-florbetapir (Amyvid) positron emission tomography (PET) scans results
기간: 12 Months
|
Change from baseline standardized uptake values in select regions of interest at 12 months
|
12 Months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cognitive test results: Story recall
기간: 12 months
|
Change in baseline Story Recall results at 12 months
|
12 months
|
|
Cognitive Test Results: Change in Montreal Cognitive Assessment (MOCA)
기간: 12 Months
|
Change in baseline MOCA score results at 12 months
|
12 Months
|
|
Cognitive Test Results: Change in Clinical Dementia Rating Scale
기간: 12 Months
|
Change in baseline Clinical Dementia Rating Scale score at 12 months
|
12 Months
|
|
Cognitive Test Results: Digit span
기간: 12 Months
|
Change in baseline Digit span results at 12 months
|
12 Months
|
|
Cognitive Test Results: Letter number sequencing
기간: 12 Months
|
Change in baseline Letter number sequencing results at 12 months
|
12 Months
|
|
Cognitive Test Results: Stroop Test Results
기간: 12 Months
|
Change in baseline Stroop Test Results at 12 months
|
12 Months
|
|
Cognitive Test Results: Symbol Digit Modalities Test
기간: 12 Months
|
Change in baseline Symbol Digit Modalities Test score at 12 months
|
12 Months
|
|
Cognitive Test Results: Visuo-Spatial Learning Test
기간: 12 Months
|
Change in baseline Visuo-Spatial Learning Test results at 12 months
|
12 Months
|
|
Cognitive Test Results: Rey auditory verbal learning test (RVLT)
기간: 12 Months
|
Change in baseline Rey auditory verbal learning test (RVLT) score at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in CRP
기간: 12 Months
|
Change in baseline CRP values at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP3
기간: 12 Months
|
Change in baseline IGFBP3 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGFBP1
기간: 12 Months
|
Change in baseline IGFBP1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IGF-1
기간: 12 Months
|
Change in baseline IGF-1 at 12 months
|
12 Months
|
|
Inflammatory and immune markers: Change in IL-6
기간: 12 Months
|
Change in baseline IL-6 at 12 months
|
12 Months
|
|
Metabolic Markers: Change in HgbA1C
기간: 12 Months
|
Change in baseline HgbA1C at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Estradiol
기간: 12 Months
|
Change in baseline Estradiol at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Follicle Stimulating Hormone (FSH)
기간: 12 Months
|
Change in baseline Change in Follicle Stimulating Hormone (FSH) at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Leptin
기간: 12 Months
|
Change in baseline Leptin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in Adiponectin
기간: 12 Months
|
Change in baseline Adiponectin at 12 months
|
12 Months
|
|
Metabolic Markers: Change in homeostatic model assessment of insulin resistance (HOMA-IR)
기간: 12 Months
|
Change in baseline HOMA-IR values at 12 months; Calculated based on fasting glucose and insulin test results.
|
12 Months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Evan Yu, Fred Hutch/University of Washington Cancer Consortium
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- RG1001903
- 9939 (FHCRC)
- NCI-2018-01618 (레지스트리 식별자: CTRP)
- 5P30CA015704 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .